• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Special Report: Psychedelics in Medicine Part 1: Psychedelics as a potential therapeutic option for psychiatric conditions

byJack LennonandAlex Chan
May 10, 2021
in Chronic Disease, Neurology, Psychiatry
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

RELATED REPORTS

No Content Available

Section 1: Psychedelics as a potential therapeutic option for psychiatric conditions

Psychedelic drugs, such as lysergic acid diethylamide (LSD), was of interest to molecular psychiatry in the 1950s due to its considerable chemical similarity to serotonin (5-HT). In the context of a highly regulated system, the use of psychedelics in psychiatry is not necessarily novel, but a reemerging concept.[1] They are generally considered Schedule I controlled substances (psilocybin, DMT, MDMA),[2] which traditionally are considered to purport no medical value and high potential for abuse.[3]

Despite this, psychedelic drugs such as psilocybin, in particular, have recently received increased attention with potential to treat a range of conditions.[4] Through a better understanding of pharmacokinetics and 5-HT receptor subtypes, psilocybin has become known to have a significant impact on 5-HT2A, specifically in the cerebral cortex as a non-selective serotonin agonist.[5] This is believed to inhibit thalamic filtering via GABAergic projections, which permits cortical regions to receive more sensory information.[5,6,7] However, the claustrum, a subcortical nucleus expressing high 5-HT2A receptors and projecting glutamatergic inputs to the cerebral cortex, seems to also experience positive effects following psilocybin administration.[7] There is also ample evidence that psilocybin, for example, reduces amygdalar reactivity and improves responses originating in the prefrontal and orbitofrontal cortices.[8] Clinically speaking, the culmination of these findings have led to great excitement in the application of drugs such as psilocybin for the treatment of various psychiatric conditions. In terms of dosing, there is substantial convenience and reduction of costs in administering fixed doses. It has been found that body weight does not significantly impact effects and the benefits outweigh advantages of weight-adjusted dosing.[9]

Concerns do exist regarding treatment with psychedelic drugs, with some reporting that terms such as consciousness and spiritual are misused and poorly defined.[10] Further, one must be cautious with maintaining professional boundaries in the context of psychedelic drug treatment and therapy. The combination of these treatment modalities are currently viewed positively by many, such that conventional psychotherapy could be greatly enhanced through the use of psychedelic drugs[11], effects that span the range of psychedelics and result in greater effect sizes than trials of pharmacotherapy or psychotherapy alone.[12]  While much research remains regarding safety and efficacy, guidelines are in place that have resulted in very few persisting adverse reactions.[13] Areas of improvement include but are not limited to ethics, trial design, and unambiguously defining outcomes.[11] The current reality is that psychedelics demonstrate unique potential for the treatment of psychiatric conditions and are likely to become more widespread as research continues to explore this area.[14]

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: psyechedelics
Previous Post

Special Rewind: Psychedelics Edition. May 10, 2021

Next Post

Lumasiran decreases urinary oxalate excretion in Primary Hyperoxaluria Type 1

RelatedReports

No Content Available
Next Post
Renal stones in women linked with increased risk of coronary heart disease

Lumasiran decreases urinary oxalate excretion in Primary Hyperoxaluria Type 1

Brodalumab effective in treating active psoriatic arthritis

Upadacitinib non-inferior to adalimumab for psoriatic arthritis treatment

Updated review confirms efficacy and safety of most standard treatments for latent tuberculosis infection

Rifapentine-moxifloxacin noninferior to standard of care treatment for pulmonary tuberculosis

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Vitamin and mineral supplementation associated with minimal to no benefit in the primary preventing of cardiovascular disease and cancer – US Preventative Services Task Force
  • RSVpreF vaccine prevents symptomatic respiratory syncytial virus infection
  • Incidence of Kawasaki disease found to be lower during the COVID-19 pandemic in the United States
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.